[{"id":"585a32f3-28c6-4f08-90c9-99a6438a2ce5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02987829","created_at":"2021-04-24T03:55:23.010Z","updated_at":"2024-07-02T16:36:31.325Z","phase":"Phase 1/2","brief_title":"Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients","source_id_and_acronym":"NCT02987829","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TRC253"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 10/06/2019","primary_completion_date":" 10/06/2019","study_txt":" Completion: 11/09/2020","study_completion_date":" 11/09/2020","last_update_posted":"2021-04-23"}]